Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $173.52 which represents a decrease of $-0.27 or -0.16% from the prior close of $173.79. The stock opened at $173.22 and touched a ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Sage (SAGE) stock fell 18% post-market after the company released its Q3 earnings report and said it was ending development ...

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Biogen (BIIB – Research Report) today and set a price target of ...

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.